Angiochem Inc.
Records under this name other than the patents Angiochem Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,828,925 | Etoposide and Doxorubicin Conjugates for Drug Delivery Lapsed on the fee record Ended Sep 9, 2026 · High confidence | Lapsed on the fee record | Ended Sep 9, 2026 | High confidence |
| US 9,914,754 | Conjugates of neurotensin or neurotensin analogs and uses thereof Lapsed on the fee record Ended Mar 13, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 13, 2026 | From the USPTO record |
| US 9,713,646 | Potentiation of anticancer agents Lapsed on the fee record Ended Jul 25, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 25, 2025 | From the USPTO record |
| US 7,557,182 | Molecules for Transporting a Compound Across the Blood-Brain Barrier Term ended Term ended Jul 21, 2025 · High confidence | Term ended | Term ended Jul 21, 2025 | High confidence |
| US 8,828,949 | Aprotinin Polypeptides for Transporting a Compound Across the Blood-Brain Barrier Term ended Term ended Jul 21, 2025 · High confidence | Term ended | Term ended Jul 21, 2025 | High confidence |
| US 9,365,634 | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues Lapsed on the fee record Ended Jun 14, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jun 14, 2024 | From the USPTO record |
| US 9,173,891 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog Lapsed on the fee record Ended Nov 3, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 3, 2023 | From the USPTO record |
| US 7,902,156 | Aprotinin Polypeptides for Transporting a Compound Across the Blood-Brain Barrier Lapsed on the fee record Ended Mar 8, 2023 · High confidence | Lapsed on the fee record | Ended Mar 8, 2023 | High confidence |
| US 9,687,561 | Peptide-dendrimer conjugates and uses thereof Lapsed on the fee record Ended Jun 27, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jun 27, 2021 | From the USPTO record |
| US 8,921,314 | Conjugates of GLP-1 agonists and uses thereof Lapsed on the fee record Ended Dec 30, 2018 · From the USPTO record | Lapsed on the fee record | Ended Dec 30, 2018 | From the USPTO record |